en
Scientific article
English

Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir

Published inAIDS, vol. 26, no. 5, p. 567-575
Publication date2012
Abstract

Tenofovir is associated with reduced renal function, but it is not clear whether there is a greater decline in renal function when tenofovir is co-administered with a boosted protease inhibitor rather than with a nonnucleoside reverse transcriptase inhibitor (NNRTI).

Keywords
  • Adenine/adverse effects/analogs & derivatives
  • Adult
  • Benzoxazines/adverse effects
  • Drug Therapy, Combination/adverse effects/methods
  • Female
  • Glomerular Filtration Rate/drug effects
  • HIV Infections/drug therapy
  • HIV Protease Inhibitors/administration & dosage/adverse effects
  • Humans
  • Kidney/drug effects/physiopathology
  • Lopinavir/adverse effects
  • Male
  • Middle Aged
  • Oligopeptides/adverse effects
  • Organophosphonates/adverse effects
  • Pyridines/adverse effects
  • Reverse Transcriptase Inhibitors/administration & dosage/adverse effects
  • Ritonavir/adverse effects
  • Treatment Outcome
Research group
Citation (ISO format)
YOUNG, Jim et al. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. In: AIDS, 2012, vol. 26, n° 5, p. 567–575. doi: 10.1097/QAD.0b013e32834f337c
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal0269-9370
552views
0downloads

Technical informations

Creation12/03/2013 2:47:00 PM
First validation12/03/2013 2:47:00 PM
Update time03/14/2023 8:40:03 PM
Status update03/14/2023 8:40:03 PM
Last indexation05/02/2024 1:31:20 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack